Why is Aurobindo Pharma falling/rising?

As of 31-Jul, Aurobindo Pharma Ltd. is experiencing a decline in its stock price, currently at 1,140.95, which reflects a decrease of 12.55 or 1.09%. The stock has been underperforming recently, having fallen consecutively for the last two days with a total return of -1.48% during this period. Although it outperformed its sector by 0.4% today, the stock's delivery volume has decreased by 4.31% compared to the five-day average, indicating a drop in investor participation. Over the past year, Aurobindo Pharma has generated a return of -20.54%, despite a 5.3% increase in profits, suggesting that while the company's fundamentals may be improving, market sentiment remains weak. The company has a low debt-to-equity ratio and an attractive valuation, which could provide some support for the stock, but the high PEG ratio of 3.7 indicates that the stock may be overvalued relative to its growth expectations.
In the broader market context, Aurobindo Pharma's short-term performance shows a 1-week return of +2.03%, contrasting with the Sensex's decline of -1.22% during the same period, indicating some relative strength. However, the stock's year-to-date performance is notably poor at -14.55%, while the Sensex has gained 3.90%, highlighting a significant underperformance against the benchmark. This divergence suggests that while the stock may have some positive attributes, such as high institutional holdings at 41.31%, the overall market conditions and investor sentiment are currently unfavorable, contributing to the stock's recent decline.